ArticleMolecular medicine (Cambridge, Mass.)2025
Cytokine production of mononuclear leukocytes in response to respiratory syncytial virus is increased in COPD but suppressed in non-COPD tobacco smokers.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of aerosol inhalation of recombinant human interferon-α2b injection in children hospitalized with human adenovirus pneumonia: a prospective, multicenter, randomized, controlled trial in China.International journal of surgery (London, England) · 2026Article
- Exploring CCND1 as a Key Target ofCurrent issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) induces exacerbations of chronic obstructive pulmonary disease (COPD) that are critical for disease progression and burden. COPD subjects have an increased susceptibility to viral respiratory infections. We aimed to identify underlying systemic immune pathologies that could be used as drug targets to reduce exacerbations.
methodsPeripheral blood mononuclear cells were isolated from 16 healthy never smokers, 17 current smokers without airflow limitation, and 17 COPD subjects. The cells were cultured and infected with RSV for 24 h or seven days. IFNα, T-cell- and inflammatory cytokines, the expression of interferon-stimulating genes (ISGs), and virus load in supernatants were measured by ELISA or real-time PCR, respectively. Data were compared between the three patient groups.
resultsRSV induced CCL2, CCL5, IFNα, IFNγ, IL1-β, IL-6, IL-8, and TNFα but not IL-4, IL-5, IL-17, GM-CSF, and TGFβ. CCL2 was unchanged between the groups. All other cytokines were either increased or produced for a longer period of time in COPD but were reduced or not produced at all in smokers. Virus copy numbers were increased in COPD but reduced in smokers. RSV induced MxA, OAS, and Viperin expression with differences between the groups.
conclusionCirculating immune cells in COPD might cause cytokine overproduction in response to RSV after recruitment to the site of infection and might contribute to the increase in inflammation in exacerbations. This might be explained by differences in RSV replication efficacy and ISG expression. We provide first indication for ISGs and circulating cells as drug targets to reduce or prevent exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.